^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
leflunomide
i
Other names: HWA 486, SU 101, SU101, HWA486, SU-101, HWA-486
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Generic mfg.
Drug class:
DHODH inhibitor
Related drugs:
10d
PRIMERA001: Comparing the effectiveness of our tailor-made management approach with routine care from a clinical, patient's as well as an economic point of view. Tailoring of treatment is done by taking the presence of autoantibodies and the quick response to glucocorticoids and JAK inhibitors into account. (2024-511530-12-01)
P4, N=300, Active, not recruiting, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | Not yet recruiting --> Active, not recruiting
Enrollment closed
|
hydroxychloroquine • Simponi (golimumab) • leflunomide • methylprednisolone acetate
14d
Study of a lipid extract from Eryx snakes in rat adjuvant-induced arthritis under a therapeutic regimen: comparison with methotrexate and leflunomide. (PubMed, Inflammopharmacology)
Semi-quantitative histological scoring confirmed that LEES effectively limited articular structural damage without inducing the hepato-splenic toxicity associated with methotrexate. These findings indicate that LEES possesses multimodal immunomodulatory and analgesic actions with a highly favorable tolerability profile, supporting its further preclinical development as a potential adjunct or alternative to existing therapies.
Preclinical • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
|
methotrexate • leflunomide
14d
Biomimetic Nanoplatform for Targeted Glioblastoma Therapy via Concurrently Triggering GPX4/DHODH Mediated Ferroptosis. (PubMed, Adv Sci (Weinh))
Therefore, in the present study, a multifunctional nanoplatform, hollow mesoporous manganese dioxide (H-MnO2)-hemin-leflunomide@membrane (MHL@M), is proposed and fabricated...Both in vitro and in vivo results demonstrate that MHL@M has excellent tumor-targeting, TME-responsive, and ferroptosis activation capacities. This study provides a solid foundation for the development of ferroptosis-based therapeutic strategies for GBM.
Journal
|
GPX4 (Glutathione Peroxidase 4)
|
leflunomide
20d
Leflunomide in Previously Treated Metastatic Triple Negative Cancers (clinicaltrials.gov)
P1/2, N=17, Completed, Joseph Sparano | Active, not recruiting --> Completed
Trial completion
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
|
ER positive • HER-2 negative • PIK3CA mutation • HER-2 negative + ER positive
|
leflunomide
30d
ARAVA PASS: A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia (clinicaltrials.gov)
P=N/A, N=3500, Active, not recruiting, Sanofi | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Nov 2025 --> Mar 2026
Trial completion date • Trial primary completion date
|
leflunomide
1m
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients (clinicaltrials.gov)
P2, N=27, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=56 --> 27 | Trial completion date: Jul 2026 --> Jan 2027 | Trial primary completion date: Jul 2026 --> Jan 2027
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
leflunomide
2ms
"Effect of Vitamin E (α-Tocopherol) on Clinical Activity and Inflammation in Rheumatoid Arthritis" (clinicaltrials.gov)
P2/3, N=46, Recruiting, University of Guadalajara | Not yet recruiting --> Recruiting
Enrollment open
|
leflunomide
2ms
"Effect of Vitamin E (α-Tocopherol) on Clinical Activity and Inflammation in Rheumatoid Arthritis" (clinicaltrials.gov)
P2/3, N=46, Not yet recruiting, University of Guadalajara | Trial completion date: Dec 2027 --> Jan 2027 | Trial primary completion date: Jun 2025 --> Dec 2026
Trial completion date • Trial primary completion date
|
leflunomide
2ms
Pharmacogenetics of Leflunomide in the Management of Rheumatoid Arthritis (clinicaltrials.gov)
P=N/A, N=110, Recruiting, Foundation University Islamabad
New trial
|
leflunomide
2ms
Trastuzumab Combined With Chemotherapy and Leflunomide for HER2-Expressing Unresectable Advanced Biliary Tract Malignancies: An Open-Label, Single-Arm, Phase II Study (ChiCTR2500112844)
P2, N=53, Not yet recruiting, The Third Affiliated Hospital of Naval Medical University (Shanghai Eastern Hepatobiliary Surgery Hospital); The Third Affiliated Hospital of Naval Me
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 amplification • HER-2 expression • HER-2 underexpression
|
Herceptin (trastuzumab) • leflunomide
2ms
Leflunomide Treatment for MEN1 Patients - the LUMEN1 Trial (clinicaltrials.gov)
P=N/A, N=3, Terminated, University Hospital, Basel, Switzerland | N=15 --> 3 | Active, not recruiting --> Terminated; The study was prematurely terminated due to significant difficulties in recruiting participants, arising from the extremely rare nature of the targeted gene mutation.
Enrollment change • Trial termination
|
leflunomide
2ms
Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease (clinicaltrials.gov)
P4, N=100, Recruiting, Tongji Hospital | Enrolling by invitation --> Recruiting | Trial completion date: Dec 2025 --> Mar 2027 | Trial primary completion date: Dec 2025 --> Oct 2026
Enrollment status • Trial completion date • Trial primary completion date
|
cyclophosphamide • sirolimus • Actemra IV (tocilizumab) • leflunomide
Share via
